O'Cearbhaill, R. E., Wolfer, A., Disilvestro, P., O'Malley, D. M., Sabbatini, P., Shohara, L., Schwarzenberger, P. O., Ricciardi, T., Macri, M., Ryan, A., Venhaus, R. R., Bryan, J. K., Wong, P., Homicsko, K., Kandalaft, L., Rusakiewicz, S., Harari, A., Monk, B. J., & Coukos, G. (n.d.). 945PA phase I/II study of chemo-immunotherapy with durvalumab (durva) and pegylated liposomal doxorubicin (PLD) in platinum-resistant recurrent ovarian cancer (PROC). Annals of oncology, 29, . http://access.bl.uk/ark:/81055/vdc_100095200168.0x000040